This article on low dose rate (LDR) prostate brachytherapy reviews long-term results, patient selection and quality of life issues. Mature results from the United States and United Kingdom are reported and issues regarding definitions of biochemical failure are discussed. Latest data comparing brachytherapy with radical prostatectomy or no definitive treatment and also the risk of secondary malignancies after prostate brachytherapy are presented. Urological parameters of patient selection and quality of life issues concerning urinary, sexual and bowel function are reviewed. The position of prostate brachytherapy next to surgery as a first-line treatment modality is demonstrated.
Introduction
Prostate cancer is the most commonly diagnosed malignancy in Western men. 1 The lifetime risk for a man in the United Kingdom to be diagnosed with prostate cancer is 1 in 14. 2 There are in excess of 300 000 new cases of prostate cancer per year diagnosed in Europe, and in 2004 there were 35 000 new cases of prostate cancer in the United Kingdom alone. 3 The optimal therapy for men with localized prostate cancer remains uncertain, as there is a lack of randomized trials. Available evidence from non-randomized cohort studies suggest that all modalities have comparable results, in terms of cancer control and survival. [4] [5] [6] As a result, patients with localized prostate cancer are often faced with the dilemma of choosing a treatment based on the side-effect profile and the potential impact on the quality of life.
Brachytherapy represents a treatment option with a relatively favourable side-effect profile and encouraging long-term results are reported from the United States where it is the most popular form of treatment for early prostate cancer. A similar uptake is expected in the United Kingdom and Europe in the next 5 years. 
Long-term results
Mature results coming from the United States, which report brachytherapy as either monotherapy or in combination with external beam radiotherapy (EBRT), are very encouraging. The Seattle group recently reported 15-year data from patients treated with brachytherapy plus EBRT, 8 with overall biochemical relapse-free survival (BRFS) of 74%. When stratified into risk groups (see Table 1 ), a BRFS of 88, 80 and 53% respectively is demonstrated. This compares favourably to the 15-year results after radical prostatectomy where the overall 15-year BRFS is 66%. 9 Stock et al.
10 published 10-year data for brachytherapy as monotherapy, focussing on disease-specific survival (DSS) rather than BRFS. Results showed a 96% DSS at 10 years. In addition, kinetics of the rising prostate-specific antigen (PSA) post-treatment were examined. Patients who did not experience a PSA failure had 100% DSS which was not statistically different from those patients with a PSA failure, but a doubling time of more than 10 months (98%). These rates were in marked contrast to the 52% DSS in patients with a doubling time less or equal to 10 months.
Series based on modern brachytherapy equipment and techniques are expected to reflect improved BRFS with improved planning software and ultrasound imaging. Indeed, a more recent series from Merrick et al. 11 reported an 8-year BRFS of 98, 98 and 88% for low, intermediate and high-risk patients treated with brachytherapy ± EBRT.
These excellent results from the United States have been similarly replicated in the United Kingdom. Recently published results from our centre (Guildford) show a 5-year BRFS of 93% overall for the first 300 patients treated, which when stratified by risk factors show a 96, 89 and 93% 5-year BRFS for low, intermediate and high-risk groups, respectively. 12 Another area of continuous evolution is the definition of biochemical failure. [13] [14] [15] The most widely used definition is that of the American Society for Therapeutic Radiology and Oncology (ASTRO) which defines biochemical failure as three consecutive rises in PSA level more or equal to 3 months apart. The time to failure is defined as the midpoint between the lowest serum PSA level and the first increase. 16 The recent study of Kuban et al. 17, 18 from Houston, Texas published in 2006 proposes that when biochemical failure is defined as an increase of 2 ng ml À1 above the PSA nadir, it shows the best sensitivity and specificity. This is better known as 'The Houston þ 2 Definition'. Figure 1 shows how the same data from a patient may be interpreted using the current possible different definitions of failure. Postradical prostatectomy failure of treatment is usually defined as a PSA rise above 0.2 ng ml À1 , 19 in this case with the patient deemed as failing at 36 m. The ASTRO definition requires month 48 to have been reached before the patients is censured as failing at 33 m. The ASTROKattan, 20 ASTRO-last call 21 and Houston þ 2 definitions give the following times of failure 30, 48 and 54 m respectively. However, one-third of patients treated with brachytherapy will experience a PSA bounce within the first 3 years, typically of a magnitude of o4 ng ml À1 . 22, 23 In view of this, our centre in Guildford typically waits until the PSA has past 4.0 ng ml À1 before initiating investigations to look for recurrent prostate cancer, namely MRI, bone scan and prostate biopsy.
In a large retrospective study Tward et al. 24 analysed 60 000 men diagnosed with organ confined low and moderate grade prostate cancer. Patients were treated with prostatectomy, brachytherapy or no definitive treatment. Overall a better survival was observed in men treated with definitive therapy (brachytherapy or radical prostatectomy) Po0.001. There was no statistically significant difference in prostate cancer-specific mortality or any cause mortality between prostate brachytherapy and radical prostatectomy irrespective of patients' age. This is the first study to demonstrate the value of active treatment (brachytherapy) over a watchful waiting approach. It mirrors the results which were obtained in a prospective study from Holmberg et al. 25 randomizing patients for radical prostatectomy or watchful waiting prospectively, with similar recruitment time and patient demographics.
A muted concern related to radiation treatments for prostate cancer is the risk of secondary malignancies. Moon et al. 26 analysed retrospectively 140 767 men with incident prostate cancer and examined the association between secondary cancers after radiotherapy during a mean period of 10.6 years. The results of this study show that men who received EBRT alone had statistically significant higher probability of developing secondary cancers, especially of the bladder and rectum. However, patients who received brachytherapy alone or brachytherapy combined with EBRT had no statistically significant increased risk of secondary malignancies. 27 
Patient selection
There have been some recent advances in the urological parameters of patient selection. A recent study published in 2007 from the United Kingdom shows that a prostate size of 450 ml should not be a contraindication for prostate brachytherapy and indeed may not require hormonal cytoreduction in the absence of pubic arch interference. 28 There was no statistically significant difference between the group with prostate volumes larger than 50 cc and those with volumes o50 cc in intraor post-operative prostate dosimetry (D 90 , V 100 and V 150 ). The incidence of acute urinary retention post-implant between the two groups was not statistically different. Pubic arch interference occurring in the bigger prostates may be overcome by adjusting the position of the patient.
The role of transurethral resection of the prostate (TURP) or bladder neck resection (BNR) prior to brachytherapy is also being reviewed. Initial reports in 1991 described a 17% risk of urinary incontinence in TURP patients. 29 However, as techniques evolved Wallner et al. 30 reported that the risk of incontinence is as low as 6% using a peripherally loaded technique and Stone et al. 31 reported no incontinence in a group of 43 patients with TURP prior to their implant. Cesaretti et al.
32 did a dosimetric analysis of patients having brachytherapy post-TURP and concluded that patients with substantial TURP defect received the same quality implant as patients with no or small TURP defect. At our centre in Guildford, we frequently perform BNR on patients with small prostates (o40 cc) but obstructive signs or symptoms and on patients with high bladder neck evident on sagittal transrectal ultrasound visualization and endoscopically (Figure 2 ).
Quality of life
Surgery and radiation therapy (EBRT or 125 I brachytherapy) have equivalent outcomes in terms of cancer control and survival when used as treatment for early Figure 1 An illustration of the effects of using different definitions of failure based on the same prostate-specific antigen (PSA) reading from a patient between 24 and 60 months post-treatment. LDR brachytherapy S Voulgaris et al prostate cancer. 5, 6, 21 Contemporary patients tend to place equal emphasis on the expected prostate cancer survival outcomes and post-treatment quality of life associated with each treatment modality. 33 Therefore issues concerning quality of life after treatment for localized prostate cancer are becoming increasingly important.
The main domains of bother after localized prostate cancer treatments are sexual, urinary and bowel function. 34 With regards to sexual function, patients with a 125 I implant have significantly better sexual function than those with high-dose EBRT or radical prostatectomy. 33 In our centre, approximately 84% of men potent prior to brachytherapy retain their potency, with or without the use of a PDE-5 inhibitor, using our novel technique of placing stranded seeds peripherally and loose seeds implanted via a Mick applicator centrally. 35 With regards to urinary symptoms in total, the picture is less clear. Incontinence is very rare following brachytherapy with an incidence of less than 1% in our centre. 36 Fulmer et al. 37 reported an incidence of 1% of new pad use 1-year post-treatment. However, Frank et al. 33 using the Expanded Prostate Cancer Index Composite (EPIC) survey concluded that there was no statistically significant difference in urinary bother (P ¼ 0.058) or urinary function (P ¼ 0.38) among radical prostatectomy and brachytherapy. This is explained due to the prevalence of storage and voiding symptoms as acute morbidity post-brachytherapy counterbalancing the more prevalent urinary incontinence of radical prostatectomy. 36, 38 Although men who undergo radical prostatectomy generally report more urinary and sexual problems compared to those undergoing radiotherapy (EBRT or low dose rate (LDR) brachytherapy), 39 bowel function and bother (diarrhoea, rectal bleeding) are consistently worse with radiotherapy. 38 It is however important to emphasize that most studies addressing this do not distinguish monotherapeutic brachytherapy from brachytherapy in combination with EBRT.
Objective evaluation of quality of life is very difficult to obtain, as this is significantly biased by individual needs of each patient and also the additional hurdle of distinguishing clinically significant versus statistically significant data. 33 Nevertheless, if sexual function and continence is important in the patient decision-making process, for appropriately selected patients, a 125 I permanent prostate brachytherapy implant may be the optimal form of definitive treatment.
Conclusions
Prostate brachytherapy for localized prostate cancer is no longer considered a new treatment. Long-term results from the United States and their reproducibility in the United Kingdom have established it as a first-line modality and placed it next to surgery in the clinician's armamentarium. It is a treatment of continuous advancement both in technique and technology with a fundamental concept; the aim of delivering high dose of radiation to the prostate whilst sparing surrounding tissues.
